Repligen Short Interest Rises 28% in March

Biotechnology company sees increased short selling activity amid market volatility

Apr. 17, 2026 at 10:23pm

Got story updates? Submit your updates here. ›

An extreme close-up of heavy, industrial bioprocessing machinery in muted tones of steel gray and chrome, conveying the complex technology that powers Repligen's critical role in the biopharmaceutical supply chain.Repligen's specialized bioprocessing equipment plays a vital behind-the-scenes role in the production of life-saving biopharmaceuticals.Waltham Today

Repligen Corporation (NASDAQ:RGEN), a leading life sciences company specializing in bioprocessing technologies, saw a significant increase in short interest during March 2026. As of March 31st, short interest totaled 5,556,333 shares, up 28% from the previous reporting period on March 15th.

Why it matters

The rise in short interest for Repligen reflects broader market volatility and uncertainty around the biotech sector. Short sellers may be betting on potential headwinds for the company, though Repligen remains a key supplier of critical products for the biopharmaceutical industry.

The details

Repligen's short interest now accounts for 10% of its total shares outstanding. Based on the company's average daily trading volume, the current short interest ratio stands at 6.3 days, indicating that it would take short sellers just over a week to cover their positions.

  • As of March 31, 2026, Repligen had 5,556,333 shares shorted.
  • This represents a 28% increase from the 4,340,746 shares shorted as of March 15, 2026.

The players

Repligen Corporation

A life sciences company that develops and manufactures high-value consumable products for bioprocessing applications, specializing in technologies that support the development and production of biopharmaceuticals.

Wealth Enhancement Advisory Services LLC

An institutional investor that increased its stake in Repligen by 1.9% during the third quarter of the previous year.

Got photos? Submit your photos here. ›

What’s next

Investors will be closely watching Repligen's upcoming financial results and guidance to gauge the company's performance and outlook amid the increased short interest.

The takeaway

The rise in short interest for Repligen reflects broader market volatility and uncertainty around the biotech sector, though the company remains a key supplier of critical products for the biopharmaceutical industry.